# OnCo record fgfr-signalling (pathway). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/pathways/fgfr-signalling/>
  a schema:BioChemEntity ;
  onco:kind "pathway" ;
  schema:identifier "fgfr-signalling" ;
  schema:name "FGF / FGFR signalling"@en ;
  schema:description "Fibroblast growth factor receptors are growth antennas on the cell surface. Bladder cancer mutates FGFR3, bile duct cancer fuses FGFR2 to other genes, and stomach cancer overproduces FGFR2b; each has its own drug, and each brings a tell-tale side effect (high phosphate) because the same receptors control phosphate in the kidney."@en ;
  schema:url <https://onco.cc/pathways/fgfr-signalling/> ;
  schema:dateModified "2026-09-04"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Fibroblast_growth_factor_receptor> ;
  schema:citation <https://en.wikipedia.org/wiki/Fibroblast_growth_factor_receptor> ;
  onco:cancers <https://onco.cc/cancers/urothelial/>, <https://onco.cc/cancers/cholangiocarcinoma/>, <https://onco.cc/cancers/gastric/> ;
  onco:targets <https://onco.cc/targets/fgfr2/>, <https://onco.cc/targets/kras/>, <https://onco.cc/targets/pik3ca/> ;
  onco:drugs <https://onco.cc/drugs/erdafitinib/>, <https://onco.cc/drugs/pemigatinib/>, <https://onco.cc/drugs/futibatinib/>, <https://onco.cc/drugs/bemarituzumab/> ;
  onco:pathways <https://onco.cc/pathways/ras-mapk/>, <https://onco.cc/pathways/pi3k-akt-mtor/> .